Abiant is using advanced imaging technology to
accelerate the development of new therapeutics. A
primary focus is on positron emission tomography
(PET) imaging of the central nervous system,
oncology, and inflammatory disease.
Using proprietary data collection, processing, and
analysis methods to achieve high quality and reliability,
we conduct imaging studies to provide critical
information regarding compound action. This
information can help pharmaceutical developers to
make earlier drug development decisions, reducing
time, cost, and risk. We have also developed a
Reference Library of image data for discovery and
comparison to novel compounds. We have programs
underway relating to diagnostic applications.
With a team approach, we strive to combine scientific
and operational excellence in order to meet our
customers' needs and to advance the treatment of
disease.
accelerate the development of new therapeutics. A
primary focus is on positron emission tomography
(PET) imaging of the central nervous system,
oncology, and inflammatory disease.
Using proprietary data collection, processing, and
analysis methods to achieve high quality and reliability,
we conduct imaging studies to provide critical
information regarding compound action. This
information can help pharmaceutical developers to
make earlier drug development decisions, reducing
time, cost, and risk. We have also developed a
Reference Library of image data for discovery and
comparison to novel compounds. We have programs
underway relating to diagnostic applications.
With a team approach, we strive to combine scientific
and operational excellence in order to meet our
customers' needs and to advance the treatment of
disease.
| Copyright 2006-2007 Abiant, Inc. |
About Us
 | |  | |  | |  |
Advanced BioImaging to Accelerate New Therapeutics
| Accelerating improved therapeutics |
| Understanding compound action |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |